Browse by Phase
Phase 3 Clinical Trials
Phase 3 trials compare a new drug or treatment against the current standard of care in a large population (300–3,000+ participants). Successful Phase 3 results are the basis for regulatory approval.
Total Trials
514
Recruiting Now
514
Top Conditions in Phase 3
NCT06931028 Phase 3
Recruiting
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg...
Condition
Sleep Apnea
Enrollment
260 pts
Location
China
Sponsor
Innovent Biologics (Suzhou) Co
NCT06346197 Phase 3
Recruiting
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esog...
Condition
Gastric Cancer
Enrollment
132 pts
Location
France
Sponsor
Centre Leon Berard
NCT04064060 Phase 3
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Ot...
Condition
Myelodysplastic Syndromes (MDS)
Enrollment
665 pts
Location
United States, Australia, Belgium
Sponsor
Celgene
NCT06463379 Phase 3
Recruiting
The Efficacy of Intravenous Pulse in Attaining Remission in Refractory Juvenile ...
Condition
Refractory Juvenile Idiopathic Arthritis (Despite 2 DMARDs Still Active)
Enrollment
215 pts
Location
Egypt
Sponsor
Sohag University
NCT06440694 Phase 3
Recruiting
Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The C...
Condition
Venous Thromboembolism
Enrollment
150 pts
Location
Canada
Sponsor
Ottawa Hospital Research Insti
NCT07184827 Phase 3
Recruiting
Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Unco...
Condition
Recurrent Urinary Tract Infections in Women
Enrollment
348 pts
Location
Taiwan
Sponsor
TCM Biotech International Corp
NCT06177041 Phase 3
Recruiting
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (C...
Condition
Locally Advanced Unresectable or Metastatic Gastric Cancer
Enrollment
486 pts
Location
China
Sponsor
FutureGen Biopharmaceutical (B
NCT07219966 Phase 3
Recruiting
A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disor...
Condition
Alcohol Use Disorder
Enrollment
1,100 pts
Location
United States, Belgium, China
Sponsor
Eli Lilly and Company
NCT04853342 Phase 3
Recruiting
To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients W...
Condition
Non-small Cell Lung Carcinoma
Enrollment
318 pts
Location
China
Sponsor
Allist Pharmaceuticals, Inc.
NCT07225686 Phase 3
Recruiting
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sl...
Condition
Obesity
Enrollment
250 pts
Location
United States, Australia, Canada
Sponsor
Amgen
NCT02064673 Phase 3
Recruiting
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a ...
Condition
Prostate Cancer
Enrollment
608 pts
Location
United States
Sponsor
yair lotan
NCT05873881 Phase 3
Recruiting
COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease
Condition
Heart Failure
Enrollment
2,500 pts
Location
Canada
Sponsor
Hamilton Health Sciences Corpo
NCT03016819 Phase 3
Recruiting
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarco...
Condition
Alveolar Soft Part Sarcoma
Enrollment
325 pts
Location
United States, China, Italy
Sponsor
Advenchen Laboratories, LLC
NCT04951622 Phase 3
Recruiting
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Condition
Myasthenia Gravis
Enrollment
199 pts
Location
United States, Australia, Belgium
Sponsor
Janssen Research & Development
NCT07225946 Phase 3
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metas...
Condition
Prostatic Neoplasms, Castration-Resistant
Enrollment
800 pts
Location
United States, Australia, Brazil
Sponsor
Janssen Research & Development
NCT04670666 Phase 3
Recruiting
Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes...
Condition
Type 2 Diabetes Mellitus
Enrollment
270 pts
Location
Brazil
Sponsor
EMS
NCT06303739 Phase 3
Recruiting
Psilocybin-Assisted Therapy in Treatment-Resistant Depression
Condition
Refractory Depression
Enrollment
23 pts
Location
United States
Sponsor
University of North Carolina,
NCT06972459 Phase 3
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight a...
Condition
Obesity
Enrollment
600 pts
Location
United States, Argentina, China
Sponsor
Eli Lilly and Company
NCT06341205 Phase 3
Recruiting
Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous ...
Condition
Membranous Nephropathy
Enrollment
120 pts
Location
France
Sponsor
Centre Hospitalier Universitai
NCT06806137 Phase 3
Recruiting
A Study on the Immune Response and Safety of the Second Dose of an Investigation...
Condition
Chickenpox
Enrollment
600 pts
Location
Dominican Republic
Sponsor
GlaxoSmithKline
NCT06925737 Phase 3
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Pros...
Condition
Prostate Cancer
Enrollment
1,440 pts
Location
United States, Argentina, Australia
Sponsor
Merck Sharp & Dohme LLC
NCT06593210 Phase 3
Recruiting
RSV Vaccine in Transplant Recipients
Condition
Vaccine Response Impaired
Enrollment
100 pts
Location
Canada
Sponsor
University Health Network, Tor
NCT06499857 Phase 3
Recruiting
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrilla...
Condition
Overweight or Obesity
Enrollment
200 pts
Location
United States
Sponsor
University of Chicago
NCT06123754 Phase 3
Recruiting
Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable St...
Condition
Non-small Cell Lung Cancer
Enrollment
390 pts
Location
China
Sponsor
3D Medicines (Sichuan) Co., Lt
NCT05867472 Phase 3
Recruiting
Advancing Brain Outcomes in Pediatric Critically Ill Patients Sedated With Volat...
Condition
Intensive Care Units, Pediatric
Enrollment
60 pts
Location
Canada
Sponsor
Sunnybrook Health Sciences Cen